TD-001

N/A

Report date: 2026/03/17 20:00:15

Base Information

Drug NameTD-001
Drug Alias NameTD-001
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Exatecan payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker
Mechanisms of ActionAnti-PSMADNA topoisomerase I inhibitors
TargetsProstate-Specific Membrane AntigenDNA topoisomerase I
Therapy Area/IndicationsProstatic Neoplasms, Castration-Resistant
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwitzerlandFrance
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesT.O.A.D. Oncology SA
China Registration ClassN/A

Develop Information

Active CompaniesT.O.A.D. Oncology SA
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms, Castration-Resistant
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A